If you are searching for peptide purity testing UK, start with one principle: a purity claim is only as credible as the analytical evidence behind it.

In 2026, research-grade peptide sourcing requires more than a “99% pure” statement on a product page. You need a batch-specific Certificate of Analysis (COA), independent verification, a documented analytical method, and enough information to confirm that the report relates to the vial you received.

At AXIOM Health, we view testing as part of the compound itself. Research precision depends on knowing what is present, what is absent, and how confidently the result has been established.

Important: AXIOM products are supplied for research purposes only and are not intended for human consumption, self-administration, diagnosis, treatment, or prevention of disease. Analytical purity does not establish clinical safety, efficacy, sterility for administration, or regulatory approval.

What does peptide purity actually mean?

“Purity” is often used as if it describes every quality characteristic at once. It does not.

A peptide may have a high chromatographic purity result while still requiring separate evaluation for:

• Identity
• Peptide content or assay
• Residual solvents
• Water content
• Counter-ions or salts
• Endotoxins
• Bioburden and sterility
• Degradation during storage
• Particulate contamination

For this reason, a robust quality assessment uses complementary methods. In simple terms:

• HPLC helps assess chemical purity and related impurities.
• Mass spectrometry helps confirm molecular identity.
• Additional tests may be required for other quality attributes.

This distinction matters when reviewing compounds such as BPC-157 5mg. A high purity percentage is useful, but it should be read alongside the identity data, batch information, method details, and laboratory credentials.

HPLC: the primary lens for chromatographic purity

High-performance liquid chromatography, commonly called HPLC, separates components in a sample as they pass through a chromatographic column.

For peptides, laboratories often use reverse-phase HPLC with a C18 column and ultraviolet detection near 214–215 nm. These conditions are common because peptide bonds absorb ultraviolet light in this range. However, the exact method should be stated in the report rather than assumed.

The result is displayed as a chromatogram. Each detected component appears as a peak. The principal peak is assigned to the target peptide, while smaller peaks may represent:

• Truncated sequences
• Oxidised or deamidated forms
• Deletion sequences
• Starting materials
• Solvent-related components
• Other process-related impurities

A reported purity percentage is commonly calculated from integrated peak area:

Main peak area ÷ total integrated peak area × 100

That calculation is useful, but it has limitations. It depends on the method, detection conditions, integration settings, and the components the method can detect. It should not be treated as an absolute statement that every possible impurity has been excluded.

What to inspect on an HPLC report

Please look for more than a large percentage printed on the first page. Review:

1. The complete chromatogram
   Look for a defined principal peak and a stable baseline. Shoulders, unresolved peaks, or unexplained regions require clarification.

2. The integration table
   This should show retention time, peak area, and area percentage for detected peaks. A graph without integration data provides limited evidence.

3. Method conditions
   Check for the column, mobile phases, gradient, flow rate, temperature, injection volume, and detection wavelength.

4. System suitability information
   Where available, this may include retention-time consistency, resolution, repeatability, or other controls showing that the instrument and method performed acceptably.

5. The stated basis of purity
   Confirm whether the result is area percentage, assay, content, or another measurement. These terms are not interchangeable.

A chromatogram can look clean and still be insufficient if the batch cannot be identified or the laboratory cannot be verified.

Mass spectrometry: confirming what the molecule is

Mass spectrometry measures the mass-to-charge ratio of ions. It provides a molecular fingerprint that can help establish whether the sample corresponds to the expected peptide.

Common approaches include:

• Electrospray ionisation mass spectrometry (ESI-MS)
• Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF)
• Liquid chromatography–mass spectrometry (LC-MS)
• LC-MS/MS for additional structural information

A professional report will usually state the peptide’s theoretical mass and the observed mass. It may also show the charge state, such as [M+H]+ or [M+2H]2+.

Mass spectrometry is not simply another purity percentage. Its primary value is identity confirmation. A sample could contain a highly dominant compound that is not the peptide you ordered. That is why HPLC and MS work best as complementary, orthogonal techniques.

For complex or critical research, additional characterisation may be appropriate. Depending on the compound and study design, this could include peptide mapping, amino acid analysis, residual solvent testing, water determination, endotoxin testing, or other targeted assays.

Why third-party verification matters

In-house quality control can be valuable. However, testing performed by the manufacturer or seller does not provide the same independence as testing by a separate analytical laboratory.

Third-party verification creates a clearer separation between:

• The organisation supplying the material
• The laboratory performing the analysis
• The person interpreting the result

This separation does not make a result automatically correct. You should still review the method, sample identification, scope of testing, and report integrity. However, it reduces the risk that commercial pressure will influence the analytical outcome.

For laboratories operating in the UK, ISO/IEC 17025 is an important competence standard. As UKAS explains, the standard addresses laboratory competence, impartiality, and consistent operation.

Do not treat an ISO/IEC 17025 reference as a universal guarantee. Check the laboratory’s accreditation schedule and confirm that the relevant test is within scope. Accreditation is meaningful when it applies to the method and activity being used.

COA validation: a practical UK checklist

A COA should be treated as a technical record, not a marketing accessory. Before accepting a report, work through the following checks.

1. Match the batch number

The lot or batch number on the vial should exactly match the number on the COA. A generic report or a certificate for an older batch does not verify the specific material in your possession.

2. Confirm the compound details

The report should identify the:

• Peptide name
• Sequence, where appropriate
• Molecular formula
• Theoretical molecular mass
• Observed molecular mass
• Vial or sample reference

Be cautious if the compound is identified only by a short product name with no technical detail.

3. Review both HPLC and MS data

Ideally, the COA should include chromatographic purity and an identity result. If only one method is provided, ask what the remaining quality question is and how it has been addressed.

You can also compare the document with AXIOM’s practical guide on how to read a peptide COA.

4. Check dates and traceability

Look for manufacture, test, retest, or expiry dates. These should make sense together. The COA should also show a laboratory report number, authorised signatory, and sufficient information to connect the sample to the tested batch.

5. Verify the laboratory

Search for the laboratory independently. Check its legal identity, contact details, analytical capabilities, and accreditation status where claimed. If a QR code or verification key is provided, use it rather than relying only on a PDF supplied by the seller.

6. Identify what the COA does not prove

An HPLC/MS report does not automatically demonstrate:

• Sterility
• Endotoxin control
• Correct storage after dispatch
• Stability throughout the stated shelf life
• Suitability for human or animal administration
• Clinical efficacy
• Legal authorisation as a medicine

This is particularly important when reviewing ancillary materials. If your laboratory protocol requires a reconstitution medium, review the BAC Water product page separately and assess its documentation for the intended research application. Do not infer that a peptide purity report validates the quality of the reconstitution medium.

What “compliance” means in the UK in 2026

Analytical quality and regulatory status are connected, but they are not the same thing.

The UK regulatory position depends on factors including a product’s composition, presentation, intended use, claims, and mode of action. The MHRA guidance on borderline products explains that a “research use only” label does not override the legal assessment if the product is presented or intended for medicinal use.

For genuine laboratory research, ensure that:

• Marketing avoids therapeutic or disease-treatment claims.
• Materials are clearly designated for research use only.
• No dosing or self-administration instructions are provided.
• Your organisation follows appropriate laboratory, biosafety, storage, and waste procedures.
• You retain COAs, purchase records, sample identifiers, and testing correspondence.

For formal analytical method validation, the ICH Q2(R2) guideline provides a recognised framework covering characteristics such as specificity, accuracy, precision, linearity, range, detection limits, quantitation limits, and robustness.

It is a useful benchmark for serious research environments. It is not a substitute for understanding the specific requirements of your project, institution, or regulator.

The AXIOM standard: evidence before assumption

Research integrity is built through repeatable decisions.

Choose a supplier that can explain:

1. Which laboratory tested the batch.
2. Which methods were used.
3. What the HPLC percentage represents.
4. How identity was confirmed by MS.
5. How the COA maps to the vial.
6. Which quality attributes remain outside the report’s scope.

At AXIOM Health, our focus is research-grade precision, clean formulation, third-party testing, and protocol-led clarity. We believe you should be able to inspect the evidence before beginning your work, not chase it after a result becomes difficult to interpret.

A credible purity claim should withstand scrutiny. In 2026, that means HPLC data, mass spectrometry, batch traceability, and transparent COA validation working together.

Final checklist

Before purchasing or using a research peptide, please confirm:

• The supplier provides a batch-specific COA.
• The batch number matches the vial.
• HPLC purity is supported by a chromatogram and integration table.
• Mass spectrometry confirms molecular identity.
• Test conditions are documented.
• The laboratory is identifiable and independently verifiable.
• Any accreditation claim applies to the relevant test.
• You understand what the report does and does not prove.
• The material is used only within an appropriate research and compliance framework.

Precision is not a slogan. It is a documented process.

Further reading

• UKAS: Laboratory accreditation and ISO/IEC 17025
• MHRA: Borderline products: how to tell if your product is a medicine
• ICH Q2(R2): Validation of Analytical Procedures
• AXIOM Health: How to Read a Peptide COA
• AXIOM Health BPC-157 5mg
• AXIOM Health BAC Water